Skip to main content
. 2020 Nov 12;183(4):996–1012.e19. doi: 10.1016/j.cell.2020.09.038

Figure 1.

Figure 1

SARS-CoV-2 Antibody Responses in COVID-19 Subjects

(A–C) Plasma antibody titers to SARS-CoV-2 S RBD (A) IgG, (B) IgA, and (C) IgM, divided into unexposed n = 15, acute (Ac) n = 28, and convalescent (Co) n = 15.

(D) SARS-CoV-2 RBD IgG correlates with RBD IgA.

(E–G) Plasma ELISA titers to SARS-CoV-2 S (E) IgG, (F) IgA, and (G) IgM.

(H) S IgG correlation with RBD IgG.

(I–K) Plasma ELISA titers to SARS-CoV-2 Nucleocapsid (N) protein (I) IgG, (J) IgA, and (K) IgM.

(L) N IgG correlation with S IgG.

(M) Pseudovirus (PSV) neutralizing antibody titers in unexposed, acute, and convalescent COVID-19 samples.

(N) PSV neutralizing antibody titers correlated with RBD IgG titers.

(O and P) Both (O) RBD IgG and (P) PSV neutralizing Ab titers were detectable in most acute and all convalescent COVID-19 cases at all time points tested.

The dotted line indicates LOD. Geometric mean titers with geometric SDs are indicated. Acute (Ac) = Red, Convalescent (Co) = black, Unexposed = gray. White = all COVID-19 (acute and convalescent). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001, NS = not significant. See also Figure S1.